b'<?xml version="1.0" ?>\n<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">\n<PubmedArticleSet>\n<PubmedArticle>\n    <MedlineCitation Status="MEDLINE" Owner="NLM">\n        <PMID Version="1">30710128</PMID>\n        <DateCompleted>\n            <Year>2019</Year>\n            <Month>11</Month>\n            <Day>11</Day>\n        </DateCompleted>\n        <DateRevised>\n            <Year>2020</Year>\n            <Month>05</Month>\n            <Day>08</Day>\n        </DateRevised>\n        <Article PubModel="Print">\n            <Journal>\n                <ISSN IssnType="Electronic">1474-1784</ISSN>\n                <JournalIssue CitedMedium="Internet">\n                    <Volume>18</Volume>\n                    <Issue>5</Issue>\n                    <PubDate>\n                        <Year>2019</Year>\n                        <Month>05</Month>\n                    </PubDate>\n                </JournalIssue>\n                <Title>Nature reviews. Drug discovery</Title>\n                <ISOAbbreviation>Nat Rev Drug Discov</ISOAbbreviation>\n            </Journal>\n            <ArticleTitle>Adeno-associated virus vector as a platform for gene therapy delivery.</ArticleTitle>\n            <Pagination>\n                <MedlinePgn>358-378</MedlinePgn>\n            </Pagination>\n            <ELocationID EIdType="doi" ValidYN="Y">10.1038/s41573-019-0012-9</ELocationID>\n            <Abstract>\n                <AbstractText>Adeno-associated virus (AAV) vectors are the leading platform for gene delivery for the treatment of a variety of human diseases. Recent advances in developing clinically desirable AAV capsids, optimizing genome designs and harnessing revolutionary biotechnologies have contributed substantially to the growth of the gene therapy field. Preclinical and clinical successes in AAV-mediated gene replacement, gene silencing and gene editing have helped AAV gain popularity as the ideal therapeutic vector, with two AAV-based therapeutics gaining regulatory approval in Europe or the United States. Continued study of AAV biology and increased understanding of the associated therapeutic challenges and limitations will build the foundation for future clinical success.</AbstractText>\n            </Abstract>\n            <AuthorList CompleteYN="Y">\n                <Author ValidYN="Y">\n                    <LastName>Wang</LastName>\n                    <ForeName>Dan</ForeName>\n                    <Initials>D</Initials>\n                    <Identifier Source="ORCID">http://orcid.org/0000-0001-9079-2360</Identifier>\n                    <AffiliationInfo>\n                        <Affiliation>Horae Gene Therapy Center, University of Massachusetts Medical School, Worcester, MA, USA.</Affiliation>\n                    </AffiliationInfo>\n                    <AffiliationInfo>\n                        <Affiliation>Li Weibo Institute for Rare Diseases Research, University of Massachusetts Medical School, Worcester, MA, USA.</Affiliation>\n                    </AffiliationInfo>\n                    <AffiliationInfo>\n                        <Affiliation>Department of Microbiology and Physiological Systems, University of Massachusetts Medical School, Worcester, MA, USA.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Tai</LastName>\n                    <ForeName>Phillip W L</ForeName>\n                    <Initials>PWL</Initials>\n                    <Identifier Source="ORCID">http://orcid.org/0000-0001-7409-8344</Identifier>\n                    <AffiliationInfo>\n                        <Affiliation>Horae Gene Therapy Center, University of Massachusetts Medical School, Worcester, MA, USA.</Affiliation>\n                    </AffiliationInfo>\n                    <AffiliationInfo>\n                        <Affiliation>Li Weibo Institute for Rare Diseases Research, University of Massachusetts Medical School, Worcester, MA, USA.</Affiliation>\n                    </AffiliationInfo>\n                    <AffiliationInfo>\n                        <Affiliation>Department of Microbiology and Physiological Systems, University of Massachusetts Medical School, Worcester, MA, USA.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Gao</LastName>\n                    <ForeName>Guangping</ForeName>\n                    <Initials>G</Initials>\n                    <Identifier Source="ORCID">http://orcid.org/0000-0003-0097-9012</Identifier>\n                    <AffiliationInfo>\n                        <Affiliation>Horae Gene Therapy Center, University of Massachusetts Medical School, Worcester, MA, USA. Guangping.Gao@umassmed.edu.</Affiliation>\n                    </AffiliationInfo>\n                    <AffiliationInfo>\n                        <Affiliation>Li Weibo Institute for Rare Diseases Research, University of Massachusetts Medical School, Worcester, MA, USA. Guangping.Gao@umassmed.edu.</Affiliation>\n                    </AffiliationInfo>\n                    <AffiliationInfo>\n                        <Affiliation>Department of Microbiology and Physiological Systems, University of Massachusetts Medical School, Worcester, MA, USA. Guangping.Gao@umassmed.edu.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n            </AuthorList>\n            <Language>eng</Language>\n            <GrantList CompleteYN="Y">\n                <Grant>\n                    <GrantID>P01 HL131471</GrantID>\n                    <Acronym>HL</Acronym>\n                    <Agency>NHLBI NIH HHS</Agency>\n                    <Country>United States</Country>\n                </Grant>\n                <Grant>\n                    <GrantID>R01 NS076991</GrantID>\n                    <Acronym>NS</Acronym>\n                    <Agency>NINDS NIH HHS</Agency>\n                    <Country>United States</Country>\n                </Grant>\n                <Grant>\n                    <GrantID>UG3 HL147367</GrantID>\n                    <Acronym>HL</Acronym>\n                    <Agency>NHLBI NIH HHS</Agency>\n                    <Country>United States</Country>\n                </Grant>\n            </GrantList>\n            <PublicationTypeList>\n                <PublicationType UI="D016428">Journal Article</PublicationType>\n                <PublicationType UI="D016454">Review</PublicationType>\n            </PublicationTypeList>\n        </Article>\n        <MedlineJournalInfo>\n            <Country>England</Country>\n            <MedlineTA>Nat Rev Drug Discov</MedlineTA>\n            <NlmUniqueID>101124171</NlmUniqueID>\n            <ISSNLinking>1474-1776</ISSNLinking>\n        </MedlineJournalInfo>\n        <CitationSubset>IM</CitationSubset>\n        <MeshHeadingList>\n            <MeshHeading>\n                <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D000229" MajorTopicYN="N">Dependovirus</DescriptorName>\n                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D018014" MajorTopicYN="Y">Gene Transfer Techniques</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D015316" MajorTopicYN="N">Genetic Therapy</DescriptorName>\n                <QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D005822" MajorTopicYN="N">Genetic Vectors</DescriptorName>\n                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>\n            </MeshHeading>\n        </MeshHeadingList>\n    </MedlineCitation>\n    <PubmedData>\n        <History>\n            <PubMedPubDate PubStatus="pubmed">\n                <Year>2019</Year>\n                <Month>2</Month>\n                <Day>3</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="medline">\n                <Year>2019</Year>\n                <Month>11</Month>\n                <Day>12</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="entrez">\n                <Year>2019</Year>\n                <Month>2</Month>\n                <Day>3</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n        </History>\n        <PublicationStatus>ppublish</PublicationStatus>\n        <ArticleIdList>\n            <ArticleId IdType="pubmed">30710128</ArticleId>\n            <ArticleId IdType="doi">10.1038/s41573-019-0012-9</ArticleId>\n            <ArticleId IdType="pii">10.1038/s41573-019-0012-9</ArticleId>\n            <ArticleId IdType="pmc">PMC6927556</ArticleId>\n            <ArticleId IdType="mid">NIHMS1061308</ArticleId>\n        </ArticleIdList>\n    </PubmedData>\n</PubmedArticle>\n\n</PubmedArticleSet>'